Bibliography
- DRURY AN, SZENT-GYORGYI A: The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. (1929) 68:213–237.
- VAN GALEN PJ, STILES GL, MICHAELS G, JACOBSON KA: Adenosine Ai and Ay receptors: structure-function relationships. Med. Res. Rev. (1992) 12:423–471.
- PALMER TM, STILES GL: Neurotransmitter receptors VII: adenosine receptors. Neuropharmacology (1995) 7:683–694.
- JACOBSON KA: Adenosine A3 receptors: novel ligandsand paradoxical effects. Trends Pharmacol. Sci. (1998) 19:184–191.
- SHRYOCK JC, BELARDINELLI L: Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. (1997) 79:2–10.
- •A comprehensive review of the role of adenosine and its receptors in the cardiovascular system.
- POULSEN S-A, QUINN RJ: Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. (1998) 6:619–641.
- ••This review summarises current knowledge on adenosinereceptors; the four known adenosine receptor subtypes are discussed with special reference to the opportunities for drug development.
- CRONSTEIN BN, DAGUMA L, NICHOLS D, HUTCHINSON AJ, WILLIAMS M: The adenosine/neutrophil paradox resolved: human neutrophils possess both At and A2 receptors that promote chemotaxis and inhibit 02-generation, respectively. J. Clin. Invest. (1990) 85:1150–1157.
- JORDAN JE, ZHAO Z, SATO H, VINTEN-JOHANSEN J: Adenosine Ay receptor activation attenuates reperfu-sion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. (1997) 280:301–309.
- FREDHOLM BB: Effect of adenosine, adenosine analogues and drugs inhibiting adenosine inactiva-tion on lipolysis in rat fat cells. Acta Physiol Scand. (1978) 102:191–198.
- STRONG P, ANDERSON R, COATES J, et al.: Suppression of non-esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236. Gun. Sci. (1993) 84:663–669.
- WIESER PB, PENDLETON TS: Effects of an N6-disubst-ituted adenosine derivative (B.M. 11.189) on fat cell metabolism. Biochem. Pharmacol (1979) 28:693–694.
- HENDRICKSON SC, ST. LOUIS JD, LOWE JE, ABDEL-ALEEM S: Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol. Cell Biochem. (1997) 166:85–94.
- GUPTA DK, JEWITT DE, YOUNG R, HARTOG M, OPIE LH: Increased plasma-free-fatty acid concentrations and their significance in patients with acute myocardial infarction. Lancet (1969) 2:1209–1213.
- VAN DE WERF, F: Thrombolysis for acute myocardial infarction. Why is there no extra benefit after hospital discharge Circulation (1995) 91:2862–2864.
- MILLER TD, CHRISTIAN TF, HOPFENSPIRGER MR,HODGES RO, GERSH BJ, GIBBONS RJ: Infarct size after acute myocardial infarction measured by quantitative tomographic "mTc sestamibi imaging predicts subsequent mortality. Circulation (1995) 92:334–341.
- •This paper describes the capabilities of 99mTC sestamibi imaging and its potential applications in the clinic.
- CHAREONTHAITAWEE P, CHRISTIAN TF, HIROSE K, GIBBONS RJ, RUMBERGER JA: Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J. Am. Coll. Cardiol (1995) 25:567–573.
- DRIES DL, SOLOMON AJ, GERSH BJ: Adjunctive therapy after reperfusion therapy in acute myocardial infarc-tion. Clin. Cardiol. (1998) 21:379–386.
- ALEXANDER J: Adjunctive therapy for acute myocardial infarction. Curr. Opin. Cardiol. (1997) 12:453–458.
- HANSEN PR: Myocardial reperfusion injury: experi-mental evidence and clinical relevance. Eur. Heart J. (1995) 16:734–740.
- •An easy to read review which ties together experimental evidence from animal models with clinical relevance.
- HEARSE DJ, BOLLI R: Reperfusion induced injury. Manifestations, mechanisms and clinical relevance. Trends Cardiovasc. Med. (1991) 1:233–240.
- GRANGER DN, KORTHUIS RJ: Physiologic mechanisms of postischemic tissue injury. Ann. Rev. Physiol (1995) 57:311–332.
- •A useful review summarising current thoughts on the mechanism of reperfusion injury
- SHEPHERD J, COBBE ASM, FORD et al.: Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301–1307.
- SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin survival study. Lancet (1994) 344:1383–1389.
- ALBRINK M, MAN EB: Serum triglycerides in coronary artery disease. Arch. Int. Med (1959) 103:4–8.
- BROWN DF, KINCH SH, DOYLE JT: Serum triglycerides in health and in ischemic heart disease. N Engl. J. Med. (1965) 273:947–952.
- AUSTIN MA: Epidemiology of hypertriglyceridemia and cardiovascular disease. Am. J. Cardiol. (1999) 83:13F–16F.
- MOONEY A: Treating patients with hypertriglyc-eridemia saves lives: triglyceride revisited. Curr. Med. Res. Opin. (1999) 15:65–77.
- ••An important review which stresses the importance offibrate treatment over statins.
- BREWER HB: Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am. J. Cardiol. (1999) 83:3F–12F.
- ••Names triglycerides as an independent risk factor for cardio-vascular disease and describes other risk factors associated with hypertriglyceridaemia and the metabolic syndrome.
- MAGGON KK: Linking research strategies to market opportunities for new cardiovascular drugs. Drugs News Perspect. (1995) 8:560–571.
- RYAN TJ, ANDERSON JL: ACC/AHA Guidelines for the management of patients with acute myocardial infarc-tion: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circula-tion (1996) 94:2341–2350.
- HARWOOD HJ JR, HAMANAKA ES: Modulators of dyslipidemia. Emerging Drugs (1998) 3:147–172.
- ••An excellent review of lipid-lowering drugs in developmentand on the market.
- PORKKA KVK, NUOTIO I, PAJUKANTA et al: Phenotypeexpression in familial combined hyperlipidemia. Atherosclerosis (1997) 133:245–253.
- JEPPESEN J, HEIN HO, SUADICANI P, GYNTELBERG F:Triglyeride concentration and ischemic heart disease: an eight year follow-up in the Copenhagen male study. Circulation (1998) 97:1029–1036.
- MILLER M, SEIDLER A, MOALEMI A, PEARSON TA: Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J. Am. Coll. Cardiol (1998) 31:1252–1257.
- MURRY CE, JENNINGS RB, REIMER KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 74:1124–1136.
- •A key paper describing the discovery of the endogenous cardioprotective mechanism, ischaemic preconditioning.
- AUCHAMPACH JA, GROSS GJ: Adenosine At receptor, KATp channels, and ischemic preconditioning in dogs. Am. J. Physic)]. (1993) 264:H1327–H1336
- DOWNEY JM: Ischemic preconditioning: Nature's own cardioprotective mechanism. Trends Cardiovasc. Med. (1992) 2:170–176.
- •A useful and succinct review summarising the characteristics of ischaemic preconditioning and the initial efforts to characterise the underlying mechanism.
- SCHULZ R, ROSE J, POST H, HEUSCH G: Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflugers Arch. (1995) 430:273–282.
- LOUTTIT JB, HUNT AAE, MAXWELL MP, DREW GM: The time course of cardioprotection induced by GR79236, a selective adenosine Ai-receptor agonist, in myocar-dial ischaemia-reperfusion injury in the pig. J. Cardio-vasc. Pharmacol. (1999) 33:285–291.
- NORTON ED, JACKSON EK, TURNER MB, VIRMANI R, FORMAN MB: The effects of intravenous infusions of selective adenosine Ai-receptor and A2-receptor agonists on myocardial reperfusion injury. Am. Heart.] (1992) 123:332–338.
- SCHLACK W, SCHAFER M, UEBING A, SCHAFER S, BORCHARD U, THAMER V: Adenosine A2 receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J. Cardiovasc. Pharmacol (1993) 22:89–96.
- LIANG BT, JACOBSON KA: A physiological role of theadenosine A3 receptor: sustained cardioprotection. Proc. Natl. Acad. ScL USA (1998) 95:6995–6999.
- TRACEY WR, MAGEE W, MASAMUNE H, et al.: Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc. Res. (1997) 33:410–415.
- MERKEL LA, HAWKINS ED, COLUSSI DJ, et al.: Cardiovas-cular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology (1995) 51:224–236.
- WAGNER H, MILAVEC-KRIZMAN M, GADIENT F, et al.: General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine Al receptor agonist. Drug Dev. Res. (1995) 34:276–288.
- MERKEL LA, RIVERA LM, COLUSSI DJ, PERRONE MH, SMITS GJ, COX BF: In vitro and in vivo characterization of an Al-selective adenosine agonist, RG14202. J. Pharmacol. Exp. Ther. (1993) 265:699–706.
- MERKEL L, ROJAS CJ, JARVIS MF, et al.: Pharmacological characterization of AMP 579, A novel adenosine At/A2 receptor agonist and cardioprotective. Drug Dev. Res. (1998) 45:30–43.
- HOFFMAN B, DALL'AGLIO E, HOLLENBECK C, CHANG H, REAVEN G: Suppression of free fatty acids and triglyc-erides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladeno-sine. J. Pharmacol. Exp. Ther. (1986) 239:715–718.
- GUYTON JR: Effect of niacin on atherosclerotic cardio-vascular disease. Am. J. Cardiol (1998) 82:18U–23U.
- MAHAFFEY KW, PUMA JA, BARBAGELATA A, et al.: Does adenosine in conjunction with thrombolysis reduce infarct size Results from the controlled, randomized AMISTAD trial. Circulation (1997) 96 (51)206–207.
- OGILBY JD: Role of adenosine in the cardiac catheteri-zation laboratory. Am. J. Cardiol. (1997) 79:15–19.
- ISKANDRIAN AE, JAEKYEONG H: Myocardial perfusion imaging during adenosine-induced coronary hyperemia. Am. J. Cardiol. (1997) 79:20–24.
- WILBUR SL, MARCHLINSKI FE: Adenosine as an antiar-rhythmic agent. Am. J. Cardiol (1997) 79:30–37.
- GRANGER CB: Adenosine for myocardial protection in acute myocardial infarction. Am. J. Cardiol. (1997) 79:44–48.
- GARRATT KN, HOLMES DR, MOLINA-VIAMONTE V, et al.:Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am. Heart J. (1998) 136:196–204.
- MENTZER RM, BIRJINIUK V, KHURI S, et al.: Adenosine myocardial protection. Ann. Surg. (1999) 229:643–650.
- LEESAR MA, STODDARD M, AHMED M, BROADBENT J, BOLLI R: Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation (1997) 95:2500–2507.
- MCVEY M, SMITS GJ, KITZEN J, CLARK KL, PERRONE MH:Cardiovascular pharmacology of the adenosine At/A2 receptor agonist, AMP 579; coronary hemodynamic and cardioprotective activity in canine myocardium. Cardiovasc. Pharmacol (1999) 33:703–710.
- SMITS GJ, MCVEY M, COX BF, PERRONE MH, CLARK KL: Cardioprotective effects of the novel adenosine Ai/A2 receptor agonist, AMP 579, in a porcine model of myocardial infarction. J. Pharmacol. Exp. Ther. (1998) 286:611–618.
- NAKAMURA M, ZHAO Z, CLARK KL, GUYTON RA, VINTEN-JOHANSEN J: A novel adenosine analog AMP 579 inhibits neutrophil activation, adherence and neutrophil mediated injury to coronary vascular endothelium. Circulation (1998) 98:1–666.
- MENG H, McVEY M, PERRONE M, CLARK KL: AMP 579 induces prolonged protection against myocardial infarction in minipig.j Mol. Cell Cardiol (1999) 31:Al2.
- ZANNIKOS PN, BAYBUTT RI, BOUTOUYRIE BX, SHAH B, HUNT TL, JENSEN BK: Pharmacokinetics, safety, and tolerability of single intravenous infusions of an adenosine agonist, AMP 579, in healthy male volunteers. J. Clin. Pharmacol. (1999) 39:1–9.
- MANGANO DT: Effects of acadesine on myocardial infarction, stroke, and death following surgery. JAMA (1997) 277:325–333.
- •Useful summary of the various trials which attempted to show a clinical benefit of acadesine in patients undergoing coronary artery bypass grafting.
- KARMAZYN M: The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Ann. NY Acad. Sci. (1999) 874:326–334.
- ELLIOTT GT: Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury. J. Mol. Cell Cardiol. (1998) 30:3–17.
- SCHAER GL, SPACCAVENTO LJ, BROWNE KF, et al: Benefi-cial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation (1996) 94:298–307.
- RONGEN GA, BROOKS SC, POLLARD MJ, et al.: Effect of adenosine on heart rate variability in humans. Clin. Sci. (1999) 96:597–604.
- ZHAO ZQ, NAKANISHI K, MCGEE DS, TAN P, VINTEN-JOHANSEN J: Ai receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischemia. Cardiovasc. Res. (1994) 28:270–279.
- GURDEN MF, COATES J, ELLIS F, et al.: Functional charac-terization of three adenosine receptor subtypes. Br. J. Pharmacol. (1993) 109:693–698.
- VAN SCHAICK EA, MATHOT RAA, GUBBNES-STIBBE JM, et al.: 8-Alkylamino-substituted analogs of N6-cyclopent-yladenosine are partial agonists for the cardiovascular adenosine Ai receptor in vivo. J. Pharmacol. Exp. Ther. (1997b) 283:800–808.
- •An important paper describing the characteristics of partial adenosine receptor agonists.
- VAN SCHAICK EA, DE GREEF HJMM, LANGEMEIJER MWE, SHEEHAN MJ, IJZERMAN AP, DANHOF M: Pharmacoki-net ic - pharmacodynamic modeling of the anti-lipolytic and anti-ketotic effects of the adenosine Ai-receptor agonist N6-(p-sulfopheny0 adenosine in the rat. Br. J. Pharmacol (1997a) 122:525–533.
- GARDNER CJ, TWISSELL DJ, COATES J, STRONG P: The effects of GR79236 on plasma fatty acid concentra-tions, heart rate and blood pressure in the conscious rat. Eur. Pharmacol (1994) 257:117–121.
- VAN DER GRAAF PH, VAN SCHAICK EA, VISSER SAG, DEGREEF HJMM, IJZERMAN AP, DANHOF M: Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine Ai receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J. Pharmacol. Exp. Ther. (1999) 290:702–709.
- PALMER TM, BENOVIC JL, STILES GL: Molecular basis forsubtype-specific desensitization of inhibitory adenosine receptors. J. Biol. Chem. (1996) 271:15272–15278.
Websites
- www.amhrt.org AMERICAN HEART ASSOCIATION: 1999 Heart and Stroke Statistic Update.
- ••An excellent and easy to use resource for information andstatistics regarding cardiovascular disease.
- www.dialogselect.com DIALOGSELECT DATABASE: Online searchable database accessing records listed in ADIS R&D Insight; Pharmaprojects; IMS World R&D; Derwent Patents; Incidence & Prevalence database. The Dialog Corporation.